The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Nuvation Bio Inc.

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...

Nuvation Bio (NUVB) wins U.S. FDA approval for its oral antitumor agent Ibtrozi as a treatment for certain patients with ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is ...

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...